As an unparalleled antibody development and manufacturer, Creative Biolabs is proud to offer high affinity bispecific antibodies (BsAbs) for both academic and industrial purposes. Based on our well established BsAb production platforms, we offer a variety of BsAbs for different applications: oncology, immunology, hematology, ophthalmology, osteology, pulmonary and respiratory diseases, pretargeting systems, diagnostics, and gene therapy.
The most well-known application of BsAb is cancer treatment, in which BsAbs are engineered to interfere with signaling pathways involved in tumor development, or redirect cytotoxic immune cells such as T cells and NK cells to kill tumors, or deliver radioactive therapeutics to tumor cells. Creative Biolabs offers BsAbs for signaling pathway interference, payload delivery, and immune cell recruitment, to apply to oncology.
The immune system help to maintain human health yet sometimes malfunctioning or excessive immune responses also give rise to tissue damage/destruction, altered organ growth, and altered organ function. There are various immunological disorders, including chronic inflammation, autoimmune disease, hypersensitivity, immune deficiency, and transplant rejection. BsAbs are capable of receptor signaling interference and can be applied to immunology.
Hematology concerns about blood diseases that affect the production of blood components or cause problems in blood coagulation. Blood cancers (e.g., leukemia, myeloma, and lymphoma), bleeding disorders (e.g., hemophilia), and blood clots are some examples of such diseases. Efforts have been made to apply BsAbs to the application of hematology, including treatment of different kinds of blood cancers such as acute myeloid leukemia (AML), B cell acute lymphoblastic leukemia (B cell ALL), chronic lymphocytic leukemia (CLL), and hemophilia.
In ophthalmology, many diseases are related to vascular abnormalities. For example, diabetic retinopathy (DR) and age related macular degeneration (AMD), which are the leading causes of visual loss, are due to abnormal retinal or choroidal neovascularization, respectively. BsAbs are great drug formats for next-generation therapeutics in the pharmaceutical industry for ocular disease treatment.
Functional crosstalk between osteoclasts (derived from hematopoietic stem cells and is involved in bone resorption) and osteoblasts (originated from bone marrow mesenchymal stem cells and specialized in bone apposition) is crucial for bone remodeling. Therefore, BsAbs forcing protein association can be a potential strategy in osteology research. For instance, it has been suggested that Receptor Activator of NFkB Ligand (RANKL) is an essential factor of osteoclastogenesis in vivo. BsAbs targeting RANKL itself and the RANKL/RNAK signaling pathway have been designed and generated to treat these malignant diseases.
Infection and inflammation are the main pathogenesis of pulmonary and respiratory diseases. Several pulmonary and respiratory diseases are caused or intensified by unwanted immune responses, excessive inflammation, and/or aberrant wound healing process. BsAbs can bind ligands or receptors and block unwanted signaling pathways and be useful in treating pulmonary and respiratory diseases.
BsAbs are capable of binding two or more antigens/receptors at the same time or bringing two different targets together. This character makes BsAbs widely used in the payload (drugs, radiolabels or other small molecules) delivery. In cancer therapy, radioimmunotherapy refers to the therapy in which an antibody that targets tumor-associated antigen is used to deliver cytotoxic radiation to tumor cells.
BsAbs have been used in a number of diagnostic applications such as immunoassays, radioimmunodiagnosis, and immunohistochemistry. Detection is more sensitive, rapid and specific with the help of BsAbs. Another advantage of applying BsAbs in the application of diagnostics is that BsAb diagnostic reagents avoid batch to batch variations. In the case of immunohistochemistry and immunodiagnostic assays, BsAb-mediated reactions have also improved the signal to noise ratio and simplified procedure.
Gene therapy refers to the therapeutic approach in which genes are transferred into patients’ cells for therapeutic purposes. In gene therapy, human genes can be transferred for gene correction to cure inherited diseases, while introduction of therapeutic genes from various species can benefit the treatment of many diseases. In gene therapy, a BsAb can be used as the therapeutic gene being transferred or developed as an adapter molecule.
Creative Biolabs’ leading position in the antibody engineering and drug discovery will definitely accelerate your work at BsAb development. We can tailor the correct BsAb to your special requirements. Please feel free to contact us for more information and a detailed quote.
1. Hess, C.; et al. Emerging classes of armed antibody therapeutics against cancer. MedChemComm. 2014, 5(4): 408-431.
2. Jain, M.; et al. Engineering antibodies for clinical applications. Trends in biotechnology. 2007, 25(7): 307-316.